# A Study to Test the Safety and Antibody Response of V212 in Healthy Adults (V212-004)(COMPLETED)

> **NCT00696709** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 290 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** Comparator: V212
- **BIOLOGICAL:** Comparator: Placebo

## Key facts

- **NCT ID:** NCT00696709
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12-12
- **Primary completion:** 2009-11-16
- **Final completion:** 2009-11-16
- **Target enrollment:** 290 (ACTUAL)
- **Last updated:** 2019-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00696709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00696709, "A Study to Test the Safety and Antibody Response of V212 in Healthy Adults (V212-004)(COMPLETED)". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00696709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*